Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

Yu Fujiwara; Shumei Kato; Razelle Kurzrock

doi:10.1016/j.soc.2023.12.004

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

Surg Oncol Clin N Am. 2024 Apr;33(2):197-216. doi: 10.1016/j.soc.2023.12.004. Epub 2023 Dec 18.

Authors

Yu Fujiwara¹, Shumei Kato², Razelle Kurzrock³

Affiliations

¹ Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, USA. Electronic address: Yu.Fujiwara@RoswellPark.org.
² Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA; Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.
³ Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Froedtert and Medical College of Wisconsin Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA; WIN Consortium, Paris, France; University of Nebraska, Lincoln, NE, USA.

PMID: 38401905
PMCID: PMC10894322 (available on 2025-04-01)
DOI: 10.1016/j.soc.2023.12.004

Abstract

With multiple molecular targeted therapies available for patients with cancer that correspond to a specific genetic alteration, the selection of the best treatment is essential to ensure therapeutic efficacy. Molecular tumor boards (MTBs) play a key role in this process to deliver personalized medicine to patients with cancer in a multidisciplinary manner. Historically, personalized medicine has been offered to patients with advanced cancer, but the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB. Evidence is accumulating to support feasibility and survival benefit in patients treated with matched therapy.

Keywords: Histology-agnostic; Personalized medicine; Personalized oncology; Precision medicine; Tumor-agnostic.

Publication types

Review

MeSH terms

Humans
Medical Oncology
Molecular Targeted Therapy
Neoplasms* / drug therapy
Neoplasms* / therapy
Precision Medicine

Abstract

Publication types

MeSH terms

Grants and funding